Titre : | Improving care in End-Stage Renal Disease (ESRD) : from belief in market tools to the need for complexity management. |
Auteurs : | Guillaume Le Hénanff ; Ecole des hautes études en santé publique (EHESP) (Rennes, FRA) |
Type de document : | Mémoire |
Année de publication : | 2011 |
Description : | 56p. / ann. |
Langues: | Français |
Classement : | EHMBA11/ (Master EHESP Executive Health MBA (master of business administration)) |
Mots-clés : | Rein [pathologie] ; Hémodialyse ; Soins domicile ; Transplantation organe ; Rein ; Politique santé ; Rentabilité ; Innovation ; Amélioration ; Politique prix ; Gestion risque ; Traitement ; Réglementation |
Résumé : | Is it possible (and, if yes, how?) to improve the way in which End-Stage Renal Disease (ESRD) patients are being guided towards the various treatments available by applying a better pricing policy to these treatments? This is the starting point of this study whose purpose is to make operational recommendations on this particular issue. It relies on an international literature review, cost-effectiveness data and theoretical concepts relevant for this analysis. Those elements are then taken into account to assess the current French pricing-policy. There is an international scientific and societal consensus on the fact renal transplantation has the best cost-effectiveness to treat ESRD patients. The superiority of Peritoneal Dialysis versus Haemodialysis is much debated but to preserve patient Quality of Life, home and satellite care facilities should be promoted as much as possible, all the more as they cost less than in-Centre dialysis. The various price mechanisms around the world do not play a major role contrary to the differential and level of prices. A better micro-economic understanding of dialysis facilities and nephrologist margins is needed to adapt accordingly the pricing policy. The promotion of a treatment through pricing-policy induces limitation of choice that raises ethical questions. Besides, while over-focusing on pricing tools, authorities may forget other key parameters to reach their goal, in an ever-changing field. Thus, to improve ESRD patient orientation towards the most cost-effective treatments according to their respective health status, a more democratic, comprehensive, integrated and learning collective action should be implemented. The current ESRD risk management policy, feebacks of both the Regional Health Authorities and the Biomedicine Agency offer new opportunities to manage ESRD complexity. (R.A.) |
Diplôme : | Master MBA Executive Health |
Plan de classement simplifié : | Master EHESP Executive Health (MBA) |
Exemplaires (1)
Code-barres | Cote | Support | Localisation | Section | Disponibilité |
---|---|---|---|---|---|
080199 | EHMBA11/0001 | Mémoire | Rennes | Magasin | Empruntable Disponible |
Documents numériques (1)
En ligne URL |